These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 34779392)

  • 1. Randomized, double-blind, two-way crossover bioequivalence and adhesion study, in healthy women, of a transdermal contraceptive patch with a newly sourced adhesive component at the end of shelf life vs. the EVRA patch at the beginning of shelf life.
    Sanga M; Vaughan S; Nangosyah J; Scholz V; Fonseca S
    Int J Clin Pharmacol Ther; 2022 Jan; 60(1):67-78. PubMed ID: 34779392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of a transdermal contraceptive patch with a newly sourced adhesive component versus EVRA patch: A double-blind, randomized, bioequivalence and adhesion study in healthy women.
    Parasrampuria DA; Vaughan S; Ariyawansa J; Swinnen A; Natarajan J; Rasschaert F; Massarella J; Fonseca S
    Contraception; 2020 Apr; 101(4):276-282. PubMed ID: 31935382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinyloestradiol at four application sites.
    Abrams LS; Skee DM; Natarajan J; Wong FA; Anderson GD
    Br J Clin Pharmacol; 2002 Feb; 53(2):141-6. PubMed ID: 11851637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic overview of ethinyl estradiol dose and bioavailability using two transdermal contraceptive systems and a standard combined oral contraceptive.
    Hofmann B; Reinecke I; Schuett B; Merz M; Zurth C
    Int J Clin Pharmacol Ther; 2014 Dec; 52(12):1059-70. PubMed ID: 25295716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of bleeding patterns and cycle control using two transdermal contraceptive systems: a multicenter, open-label, randomized study.
    Gruber D; Skřivánek A; Serrani M; Lanius V; Merz M
    Contraception; 2015 Feb; 91(2):105-12. PubMed ID: 25453582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of norelgestromin and ethinyl estradiol delivered by a contraceptive patch (Ortho Evra/Evra) under conditions of heat, humidity, and exercise.
    Abrams LS; Skee DM; Natarajan J; Wong FA; Leese PT; Creasy GW; Shangold MM
    J Clin Pharmacol; 2001 Dec; 41(12):1301-9. PubMed ID: 11762557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188.
    Vogler MA; Patterson K; Kamemoto L; Park JG; Watts H; Aweeka F; Klingman KL; Cohn SE
    J Acquir Immune Defic Syndr; 2010 Dec; 55(4):473-82. PubMed ID: 20842042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications of different application sites on the bioavailability of a transdermal contraceptive patch containing ethinyl estradiol and gestodene: an open-label, randomized, crossover study.
    Höchel J; Schuett B; Ludwig M; Zurth C
    Int J Clin Pharmacol Ther; 2014 Oct; 52(10):856-66. PubMed ID: 25138681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of norelgestromin and ethinyl estradiol from two consecutive contraceptive patches.
    Abrams LS; Skee DM; Wong FA; Anderson NJ; Leese PT
    J Clin Pharmacol; 2001 Nov; 41(11):1232-7. PubMed ID: 11697756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of laropiprant, a PGD2 receptor 1 antagonist, on estradiol and norgestimate pharmacokinetics after oral contraceptive administration in women.
    Schwartz JI; Liu F; Wang YH; Pramanik B; Johnson-Levonas AO; Gutierrez MJ; Lai E; Wagner JA
    Am J Ther; 2009; 16(6):487-95. PubMed ID: 19940609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adhesion Evaluation of AG200-15: An Investigational Transdermal Contraceptive Delivery System.
    Ocheltree T; Wittes J; Case J; Tuley M; Krause I; Chiodo J; Garner EIO
    Adv Ther; 2019 Dec; 36(12):3381-3389. PubMed ID: 31602573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese women.
    Kaunitz AM; Archer DF; Mishell DR; Foegh M
    Am J Obstet Gynecol; 2015 Mar; 212(3):318.e1-8. PubMed ID: 25220709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, Tolerability, and Bioequivalence of Two Formulations of Rotigotine in Healthy Chinese Subjects.
    Liu Y; Tomlinson B; Guo J; Asgharnejad M; Bauer L; Surmann E; Guo X; Elshoff JP
    Clin Ther; 2018 Jul; 40(7):1108-1121.e8. PubMed ID: 30098648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple-dose pharmacokinetics of a contraceptive patch in healthy women participants.
    Abrams LS; Skee DM; Natarajan J; Wong FA; Lasseter KC
    Contraception; 2001 Nov; 64(5):287-94. PubMed ID: 11777488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and adhesion of the Agile transdermal contraceptive patch (AG200-15) during daily exposure to external conditions of heat, humidity and exercise.
    Archer DF; Stanczyk FZ; Rubin A; Foegh M
    Contraception; 2013 Feb; 87(2):212-9. PubMed ID: 23158806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioequivalence and adhesion evaluation of transdermal clonidine following a change in excipient supplier.
    Ehrlich J; Beck B; Thiedmann R; Marzin K; MacGregor T
    Int J Clin Pharmacol Ther; 2016 Oct; 54(10):816-24. PubMed ID: 27390050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated summary of Ortho Evra/Evra contraceptive patch adhesion in varied climates and conditions.
    Zacur HA; Hedon B; Mansour D; Shangold GA; Fisher AC; Creasy GW
    Fertil Steril; 2002 Feb; 77(2 Suppl 2):S32-5. PubMed ID: 11849634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic overview of Ortho Evra/Evra.
    Abrams LS; Skee D; Natarajan J; Wong FA
    Fertil Steril; 2002 Feb; 77(2 Suppl 2):S3-12. PubMed ID: 11849630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bleeding pattern and cycle control of a low-dose transdermal contraceptive patch compared with a combined oral contraceptive: a randomized study.
    Merz M; Kroll R; Lynen R; Bangerter K
    Contraception; 2015 Feb; 91(2):113-20. PubMed ID: 25453585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of the hemostatic effect of a transdermal patch containing 0.55 mg ethinyl estradiol and 2.1 mg gestodene compared with a monophasic oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel: an open-label, randomized, crossover study.
    Junge W; Heger-Mahn D; Trummer D; Merz M
    Drugs R D; 2013 Sep; 13(3):223-33. PubMed ID: 24043457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.